おかえりなさい
アカウント登録
siteでログインする
siteで登録する
受信トレイを確認する
immatics biotechnologies
About
Immatics is a biopharmaceutical company focused on the development of immunotherapeutic substances for cancer therapy.
- 51 - 100
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $110M
- Industries
- Biotechnology,Medical,Therapeutics
- Founded date
- Jan 1, 2000
- Number Of Employee
- 51 - 100
- Operating Status
- Active
immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors.The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors.immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Oct 10, 2022 | Post-IPO Equity | $110M | 1 | — | — | Detail |
| Feb 8, 2007 | Series B | €40M | 1 | — | — | Detail |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Dellora Investments
|
— | Post-IPO Equity |
|
|
— | Series B |
